Choosing an Appropriate Treatment Regimen for Patients With Advanced Urothelial Carcinoma
July 31st 2023Experts explain how they would choose between combination therapy regimens for patients with metastatic or locally advanced urothelial carcinoma if the choice of treatment was not influenced by low supply availability.
IMbrave050: Adjuvant Therapy for High-Risk Hepatocellular Carcinoma
July 26th 2023The Oncology Brothers, joined by Muhammad Shaalan Beg, MD, share their thoughts on data from the IMbrave050 trial investigating adjuvant atezolizumab plus bevacizumab in patients with high-risk hepatocellular carcinoma.
PROSPECT: Neoadjuvant Therapy for Locally Advanced Rectal Cancer
July 26th 2023Muhammad Shaalan Beg, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data from the PROSPECT trial investigating neoadjuvant therapy regimens for the treatment of locally advanced rectal cancer.
TALAPRO-2: First-Line Therapy for Metastatic Castration-Resistant Prostate Cancer
July 13th 2023Toni Choueiri, MD, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent updates from TALAPRO-2, which studied talazoparib plus enzalutamide in first-line metastatic castration-resistant prostate cancer.
ADAURA: Overall Survival Analysis of Osimertinib in NSCLC
July 7th 2023Charu Aggarwal, MD, MPH, joins the Oncology Brothers, Rohit Gosain, MD, and Rahul Gosain, MD, to discuss recent data updates from the ADAURA trial, an overall survival analysis of osimertinib in non–small cell lung cancer (NSCLC).